Skip to main content
OpenTrials
Completed

NCT Number: NCT01097213

Neural Mechanisms Underlying Alcohol Induced Disinhibition

Forty 18-year-old social drinkers will be selected from the sample tested in specific aim 1 ("Prospective Assessment of Adolescent Drinking Trajectories With Computer-Assisted Self-administration of Ethanol (CASE)"; ClinicalTrials.gov identifier: NCT01063166). The functional magnetic resonance imaging blood-oxygen-level-dependent (fMRI BOLD) activity related to disinhibition measured with the Stop Signal task will be assessed during a continuous infusion of alcohol, clamping the arterial Breath Alcohol Concentration (aBAC) at 60 mg% for approximately one hour. It will be examined whether this fMRI BOLD activity is associated with the initial drinking trajectories and the alcohol consumption at age 18 and at age 20 identified in specific aim 1. Furthermore, fMRI will be used with the Taylor Aggression Paradigm to determine which brain areas mediate increased physical aggression during the same continuous infusion of alcohol as described above. All participants will undergo an alcohol and a placebo fMRI session.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–19 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Technische Universitaet Dresden - Dresden fMRT-Neuroimaging Center

Dresden, Saxony, 01187, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • male and female Caucasian volunteers aged 18 years/0 months to 19 years/11 months;
  • written informed consent by the subject;
  • habitual social drinking during the two months preceding participation, defined by at least one drinking day in any two weeks-interval;
  • at least one prior experience of alcohol intoxication
  • being able to abstain from tobacco use for four hours without developing nicotine withdrawal symptoms;
  • effective contraception in female participants;
  • consenting to abstain from any illegal substance use for 2 weeks prior to participation;
  • living within 15 km (9.5 miles) from downtown Dresden;
  • sufficient information concerning alcohol use in both parents and in at least four second-degree relatives

Exclusion criteria

  • prior medical treatment due to alcohol use;
  • current or prior history of any serious disease, including CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, alcohol or drug dependence, but not alcohol abuse;
  • current history of Axis-I psychiatric illness, including premenstrual dysphoric disorder;
  • current or prior history of alcohol-induced flushing reactions;
  • positive urine screen for cannabinoids, cocaine, amphetamines, opiates, or benzodiazepines;
  • light or non-drinkers: averaging less than 2 standard drinks per week in the preceding two months;
  • intention to become pregnant
  • pregnancy or positive urine pregnancy screening or breast-feeding;
  • any alcohol intake on the test day or the day before;
  • use of medications known to interact with alcohol within 2 weeks of the study;
  • positive hepatitis or HIV at screening, provided the subject consented to these tests
  • any conditions posing safety issues with the fMRI scan, such as ferromagnetic implants, cardiac pacemakers or insulin pumps

Treatment and study plan

Ethanol

Drug

Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).

Placebo - half-normal saline

Drug

Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.

Primary outcomes

  1. Alcohol consumption

    Time frame: 2 years

    Alcohol consumption, as measured by a Timeline Followback Interview.

Secondary outcomes

  1. Absolute perfusion levels assessed with arterial spin labeling

    Time frame: 1 week

  2. Behavioural Stop Signal Reaction Time (SSRT)

    Time frame: 1 week

  3. BOLD fMRI correlate of aggression

    Time frame: 1 week

  4. Taylor aggression score

    Time frame: 1 week

  5. BOLD fMRI correlate of disinhibition

    Time frame: 1 week

Sponsors and collaborators

Lead sponsor

Technische Universität Dresden

Other

Collaborators

  • Indiana University

Registry information

Official study title

Collaboration on Alcohol Self Administration in Adolescents and Young Adults - Specific Aim 2: To Examine the Effect of Acute Alcohol Administration on Forebrain Disinhibition Using Functional Magnetic Resonance Imaging (fMRI)

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Apr 1, 2010
Registry last updated
Mar 12, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.